Table 2.
Antibiotic resistance/susceptibility patterns of Enterococcus faecalis isolates
| Antibiotics | Human (n=39) |
|
Dog (n=26) |
|
Cat (n=7) |
|
Total (n=72) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | ||||
| CIP | 18 (46.2) | 21 (53.8) | 0 (0) | 26 (100) | 3 (42.9) | 4 (57.1) | 21 (29.2) | 51 (70.8) | |||
| AMP | 1 (2.6) | 38 (97.4) | 0 (0) | 26 (100) | 0 (0) | 7 (100) | 1 (1.4) | 71 (98.6) | |||
| P | 1 (2.6) | 38 (97.4) | 0 (0) | 26 (100) | 0 (0) | 7 (100) | 1 (1.4) | 71 (98.6) | |||
| VAN | 13 (33.3) | 26 (66.7) | 1 (3.8) | 25 (96.2) | 0 (0) | 7 (100) | 14 (19.4) | 58 (80.6) | |||
| B | 24 (61.5) | 15 (38.5) | 8 (30.8) | 18 (69.2) | 1 (14.3) | 6 (85.7) | 33 (45.8) | 39 (54.2) | |||
| OTET | 33 (84.6) | 6 (15.4) | 15 (57.7) | 11 (42.3) | 2 (28.6) | 5 (71.4) | 50 (69.4) | 22 (30.6) | |||
| KAN | 39 (100) | 0 (0) | 26 (100) | 0 (0) | 7 (100) | 0 (0) | 72 (100) | 0 (0) | |||
| ERY | 22 (56.4) | 17 (43.6) | 0 (0) | 26 (100) | 0 (0) | 7 (100) | 22 (30.6) | 50 (69.4) | |||
| AMX | 0 (0) | 39 (100) | 0 (0) | 26 (100) | 0 (0) | 7 (100) | 0 (0) | 72 (100) | |||
| NOR | 9 (23.1) | 30 (76.9) | 4 (15.4) | 22 (84.6) | 2 (28.6) | 5 (71.4) | 15 (20.8) | 57 (79.2) | |||
| NAL | 39 (100) | 0 (0) | 26 (100) | 0 (0) | 7 (100) | 0 (0) | 72 (100) | 0 (0) | |||
| CEP | 10 (25.6) | 29 (74.4) | 4 (15.4) | 22 (84.6) | 1 (14.3) | 6 (85.7) | 15 (20.8) | 57 (79.2) | |||
AMP: Ampicillin (30 μg), P: Penicillin G (10 μg), VAN: Vancomycin (30 μg), B: Bacitracin (10 μg), OTET: Oxytetracyclin (30 μg), KAN: Kanamycin (5 μg), ERY: Erythromycin (15 μg), AMX: Amoxicillin (25 μg), NOR: Norfloxacin (30 μg), NAL: Nalidixic acid (30 μg), CEP: Cephalothin (30 μg), and CIP: Ciprofloxacin (5 μg)